RxSight, Inc. RXST

Updated: 10 Aug 2026

NASDAQ | Biotech | Ophthalmic medical technology

No signal published yet

We already track RxSight and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow RxSight free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Ophthalmic medical technology
We're already tracking RxSight, Inc. — here are the latest events we've registered

Recent News

  • On August 5, 2026, RxSight reported second-quarter 2026 revenue of $33.7 million, including $6.5 million recognized from a new strategic collaboration with Alcon. In conjunction with appointing Aziz Mottiwala as Chief Executive Officer, the company withdrew its full-year 2026 financial guidance.

What Firelda Watch includes for RxSight, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of RxSight, Inc. will be delivered in the same format.

Want to follow RxSight, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow RxSight free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

RxSight, Inc. RXST
RxSight — follow and we'll monitor it
Follow RxSight free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.